author-photo

Michael W. Munks

Oregon Health & Science University

33

Papers

2365

Citations

Citation Trend

Filter By

Papers (33) Sort By

Journal Conference Others

PD-1 specific 'Blocking' antibodies that deplete PD-1+ T cells present An inconvenient variable in pre-clinical immunotherapy experiments.

2021 European Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (5)
PD-1 specific ‘Blocking’ antibodies that deplete PD-1+ T cells present an inconvenient variable in pre-clinical immunotherapy experiments

2020
Show All
- Source
- Cite
- Save
Citations (0)
PD-1 Specific 'Blocking' Antibodies That Deplete PD-1+ T Cells Present An Inconvenient Variable In Pre-clinical Immunotherapy Experiments

2020 bioRxiv
Show All
- Source
- Cite
- Save
Citations (0)
Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.

2020 mAbs
Show All
- Source
- Cite
- Save
Citations (0)
Author response for "PD‐1 specific ‘Blocking’ antibodies that deplete PD‐1+ T cells present An inconvenient variable in pre‐clinical immunotherapy experiments"

2020 European Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans

2017 Journal of Experimental Medicine
Show All
- Source
- Cite
- Save
Citations (29)
Enzymatic synthesis of core 2 O-glycans governs the tissue-trafficking potential of memory CD8+ T cells

2017 Science immunology
Show All
- Source
- Cite
- Save
Citations (32)
The domestic cat antibody response to feline herpesvirus-1 increases with age

2017 Veterinary Immunology and Immunopathology
Show All
- Source
- Cite
- Save
Citations (4)
Cytomegalovirus-specific CD8 T cells kill B16 melanoma cells in vivo when activated by bifunctional major histocompatibility class I - antibody fusion molecules (pMHCI-IgGs).

2015 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen.

2014 Vaccine
Show All
- Source
- Cite
- Save
Citations (13)